- Company
- ‘Leclaza combo extends survival without chemotherapy’
- by Son, Hyung Min Oct 15, 2025 11:37am
- “The MARIPOSA study is the first clinical trial to significantly extend overall survival using two targeted therapies without chemotherapy. Discussions on EGFR-mutated lung cancer treatment will now shift to focus on overall survival.” During a recent interview with Dailypharm, Professors Byoung Chul Cho and Sun Min Lim of Yonsei Cancer
- Company
- Will the MM drug Elrexfio be reimbursed this time?
- by Eo, Yun-Ho Oct 15, 2025 06:12am
- Whether progress will be made for the new multiple myeloma drug Elrexfio (elranatamab) in its second attempt to secure reimbursement in Korea is gathering attention. According to industry sources, Pfizer Korea's bispecific antibody therapy Elrexfio (elranatamab) is expected to be submitted for reimbursement review to the Health Insurance
- Company
- GSK’s myelofibrosis drug Omjjara faces reimb hurdles
- by Eo, Yun-Ho Oct 14, 2025 06:41am
- The reimbursment of GSK’s new myelofibrosis drug Omjjara has become uncertain in Korea. According to Dailypharm coverage, the reimbursement application for GSK Korea's myelofibrosis treatment Omjjara (momelotinib), which had passed the Cancer Disease Deliberation Committee of the Health Insurance Review and Assessment Service (HIRA) in M
- Company
- Hugel appoints Carrie Strom as global CEO
- by Chon, Seung-Hyun Oct 14, 2025 06:41am
- Hugel announced on October 13 that it has appointed Carrie Strom, a medical aesthetics leader and a former Senior Vice President at AbbVie, as its new Global CEO. Carrie Strom will lead Hugel's global business operations. She is highly regarded as an expert in the aesthetics field, having served for five years, from May 2020 to February th
- Company
- Entresto patent dispute near its end, yet 0 generic approval
- by Kim, Jin-Gu Oct 14, 2025 06:40am
- The patent dispute of Novartis' heart failure treatment, 'Entresto,' is nearing its final judgment. Still, generic companies may be unable to launch their products early, regardless of the ruling. To launch a generic early, companies need not only to win the patent dispute but also to secure product approval from the Ministry of Food and
- Company
- Only Ozempic undergoes DREC review for reimb, not Mounjaro
- by Eo, Yun-Ho Oct 13, 2025 06:03am
- The reimbursement journey for the two diabetes drugs that have recently gained attention as obesity treatments is taking different paths, drawing industry interest. On October 2, the Health Insurance Review and Assessment Service (HIRA)’s Drug Reimbursement Evaluation Committee reviewed Novo Nordisk Korea’s Ozempic (semaglutide) but d
- Company
- Will gastric cancer-targeted therapy Vyloy pass CDDC review?
- by Eo, Yun-Ho Oct 10, 2025 06:06am
- Attention is focused on the second attempt for insurance reimbursement of the gastric cancer-targeted anticancer drug Vyloy. According to industry sources, Astellas Korea’s Vyloy (zolbetuximab), a Claudin 18.2-positive gastric cancer-targeted therapy, is currently coordinating its schedule for review by the Health Insurance Review and As
- Company
- Boehringer wins 'Jardiance' generic trademark dispute
- by Kim, Jin-Gu Oct 10, 2025 06:05am
- In a trademark dispute over the generic-name trademark for the SGLT-2 inhibitor diabetes treatment, 'Jardiance (empagliflozin),' the original manufacturer has won a ruling from the Intellectual Property Trial and Appeal Board (hereafter, the Board). Analysis suggests that the Board's rare decision to rule in favor of the original company
- Company
- Boryung acquires global rights to Taxotere for KRW 288B
- by Chon, Seung-Hyun Oct 2, 2025 06:13am
- Boryung acquired global rights to Sanofi's anticancer drug ‘Taxotere’ for up to KRW 287.8 billion. This investment, approaching KRW 300 billion, secures a revenue stream of approximately KRW 100 billion in annual sales. Boryung announced on the 30th that it has signed a global licensing agreement with Sanofi for the global business of th
- Company
- Severe asthma drug 'Fasenra' enters 'Big 5' gen hospitals
- by Eo, Yun-Ho Oct 2, 2025 06:11am
- 'Fasenra,' a treatment for severe asthma, is now available by prescription at tertiary general hospitals. According to industry sources, AstraZeneca Korea's Fasenra (benralizumab) passed the drug committees (DC) of 'Big 5' general hospitals, including Samsung Medical Center (Seoul), Seoul National University Hospital, Seoul Asan Medical
